PSG Equity Holds Final Close of Second European Fund at more than €2.6 Billion
7.11.2023 10:00:00 EET | Business Wire | Press release
PSG Equity (“PSG”), a leading growth equity firm partnering with software and technology-enabled services companies in Europe, North America and Israel to help accelerate their growth, today announced the final close of PSG Europe II (“PSGE II”), the firm’s second Europe-focused fund, with more than €2.6 billion in commitments.
PSGE II, one of the largest growth equity funds raised to invest exclusively in European software companies, exceeded PSG’s initial target. The successful fundraise reflects the strong support received from both new and existing investors globally including state pension funds, sovereign wealth funds, family offices and high net worth individuals. PSGE II significantly exceeds the size of its predecessor, PSG Europe I, which held its final close in January 2021 with more than €1.3 billion in commitments.
Peter Wilde, Chairman of PSG, said, “We are grateful for the support that our second European fund has received from both new and existing PSG limited partners. The strong demand from a high-caliber and diversified group of investors globally demonstrates the attractiveness of Europe’s software market as well as the strength of the PSG platform and our investment approach, both in Europe and North America. The successful closing of our second European fund cements our position as one of Europe’s leading growth equity investors in the software sector.”
Market Opportunity: Digitalization of the European Economy
Europe represents the second largest IT and software market globally after North America. The software segment continues to be one of the fastest growing in the European IT market, driven by innovations such as generative AI, and is expected to reach $309 billion in size by 2026. Europe’s attractive underlying market and increasing investor focus are driving a catch-up in funding for European technology companies compared with the U.S. Furthermore, across all sectors, business processes continue to be digitized at an increasing rate thereby creating a growing market for B2B software businesses.
PSG sees the European software sector as highly fragmented with many high-quality point solution providers, often focused on either a single strategy or a single country. This market dynamic presents significant investment and growth opportunities for firms like PSG, which possess local expertise and relationships across Europe to support deal sourcing, extensive operational support capabilities and a longstanding global track record of growing B2B software businesses both organically and inorganically.
Mark Hastings, Chief Executive Officer of PSG, commented, “With PSGE II, we will be well-positioned to further capitalize on the growing investment opportunities generated by the ongoing digitalization of the European economy. We see substantial investment opportunities as companies of all sizes across all economic sectors are increasingly adopting digitization and automation tools to improve their customer service, increase productivity and secure their operations.”
PSG: A Leading Global Software Investor
With almost 200 professionals across Europe, North America and Israel, PSG has one of the largest global teams focused solely on investing in growth stage B2B software companies and is one of the sector’s most active investors in Europe. The firm’s success has been in part driven by its ability to leverage its global sourcing, operations and business functions infrastructure while bringing a local presence in and knowledge of the markets in which it invests.
PSG’s investment strategy focuses on scaling single-country, single-product software companies through organic and inorganic growth into multi-country, multi-product pan-European champions across multiple markets, supporting its portfolio companies’ global growth ambitions. Given its origins, resources and track record in the U.S., PSG can be a strong supportive partner to enable market expansion in North America.
Dany Rammal, Managing Director and Head of Europe at PSG, added, “The tremendous growth we have experienced in Europe since our inception is a testament to the success of our investment strategy and to the quality and depth of our growing team. Our cross-border M&A expertise, local knowledge and relationships, and the operational support we can provide to management teams, make us a partner of choice for ambitious and innovative founders looking to create pan-European software champions and expand internationally, including in North America. We will leverage our global software expertise to accelerate investment in innovative businesses that are using cutting edge technologies like generative AI, to drive growth and automation across cybersecurity, fintech, payments, verticalized ERP and CRM and workforce management, among others.”
PSG’s European team, which was established in 2019 and consists of 57 professionals, is headquartered in London with additional offices in Paris and Madrid. To date, PSG has made 22 platform investments in Europe with the acquisitions of Hostaway, Artur’in, Billwerk+, Hornetsecurity, Imaweb, Mapal Group, Nalanda Global, N2F, Nomentia, Powens, Rapid Data, Rodeo, Sellsy, Sesame, Signaturit, Skeepers, Sport Alliance, Tellent, Visualfabriq, Whoz, Zenchef and ZeroNorth, and facilitated over 60 add-on acquisitions with operations in 15 European countries.
About PSG Equity
PSG Equity (“PSG”) is a growth equity firm that partners with software and technology-enabled services companies to help them navigate transformational growth, capitalize on strategic opportunities and build strong teams. Having backed more than 130 companies and facilitated over 470 add-on acquisitions, PSG brings extensive investment experience, deep expertise in software and technology, and a firm commitment to collaborating with management teams. Founded in 2014, PSG operates out of offices in Boston, Kansas City, London, Paris, Madrid and Tel Aviv. To learn more about PSG, visit www.psgequity.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231106806190/en/
Contact information
Kate Pledger
kpledger@prosek.com
+447926251075
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
